agri-biotechEU parliament backs deregulation of New Ge...After two "Yes"-votes in the European Parliaments AGRI and ENVI committees, MEPs confirmed the European Commissions draft Regulation on New Genomic Technologies in plant breeding. … more ➔
partnershipJazz Pharmaceuticals licences KRAS blocker...Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules. more ➔
financingSpanish plant-based protein producer Heür...Spanish Food tech Start-up Heüra Foods secures €40m in Series B financing round to expand product distribution. more ➔
CDMOBiovian and 3P Biopharmaceuticals join for...Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN. more ➔
RNALonza and Oxford Nanopore collaborate to a...To improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA … more ➔
CRO£26m for Cystic Fibrosis Drug Trial Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors. more ➔
BiosimilarsAlvotech Advances in Biosimilar Market wit...AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA. more ➔
M&ANovozymes and Chr. Hansen Complete Merger,...Danish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, creating a new company named Novonesis. more ➔
NGT2:1 for new genomic techniquesFollowing the AGRI Committee of the European Parliament, the lead ENVI Committee has also agreed to relax the rules for the authorisation of NGTs. more ➔
M&AInnate immunity merger raises €75mForbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics. more ➔
